Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Thursday that it has met all tender offer conditions to acquire MorphoSys AG (MOR) for EUR 68 per share in cash.Novartis BidCo AG, a subsidiary of Novartis, has secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance threshold.

瑞士制药巨头诺华公司（NVS）旗下的诺华制药公司（Novartis Pharma AG）周四宣布，已满足以每股68欧元现金收购MorphoSys AG（MOR）的所有要约条件。诺华（Novartis）的子公司诺华（Novartis BidCo AG）在最初的接受期内获得了MorphoSys股东79.6%的接受率，达到了最低65%的接受门槛。

This included purchases by Novartis BidCo outside the offer for around 11.6 percent of the share capital.The settlement of the shares tendered during the initial acceptance period is expected to occur on May 23..

其中包括诺华投标公司以约11.6%的股本收购要约之外的股份。在初始验收期内投标的股份预计将于5月23日结算。。

Additional statutory acceptance period is expected to end on May 30.The company noted that the statutory two-week additional acceptance period for the offer will commence on May 17 and end on May 30. For comments and feedback contact: editorial@rttnews.comBusiness News

额外的法定接受期预计将于5月30日结束。公司注意到，要约的法定两周额外接受期将于5月17日开始，至5月30日结束。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股